<DOC>
	<DOCNO>NCT02204943</DOCNO>
	<brief_summary>This study examine biomarkers involve osteomimicry bone metastasis circulate tumor cell ( CTCs ) men mCRPC therapy bone-targeting radiopharmaceutical radium-223 . This study also examine bio-distribution radium-223 bone bone metastases men mCRPC . The investigator hypothesize bone metastasis CTCs men mCRPC commonly express marker EMT/plasticity osteomimicry , normal surround osteoblastic stroma epithelial tumor cell radium-223 target compartment include mesenchymal/osteoblastic tumor cell surround osteoblast active bone microenvironment , relative spar normal bone bone marrow .</brief_summary>
	<brief_title>Pharmacodynamic Study Radium-223 Men With Bone Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Age ≥ 18 year . 2 . Life expectancy least 12 week ( 3 month ) . 3 . Subjects must able understand willing sign write informed consent form . A sign informed consent form must appropriately obtain prior conduct trialspecific procedure . 4 . Histologically confirm diagnosis adenocarcinoma prostate . Histologic variant prostate cancer , include neuroendocrine feature permit ; however , pure small cell carcinoma prostate exclude . 5 . Presence &gt; 2 site metastatic disease bone determine bone scan CT , men optin bone biopsy , must least one site amenable radiographicallyguided metastatic biopsy determine study radiologist . 6 . Symptomatic castrationresistant bone metastatic disease determine provider . 7 . Prior concurrent therapy either abiraterone acetate enzalutamide . 8 . Ongoing ADT use LHRH agonist ( e.g . leuprolide , goserelin ) antagonist ( e.g . degarelix ) must continue therapy unless prior bilateral orchiectomy perform . 9 . Current evidence disease progression evidence one following : 1 . 2 consecutive rise PSA level separate least 1 week apart nadir PSA last systemic therapy . If nadir , 2 rise PSA value great baseline pretreatment value require immediate prior therapy , OR 2 . CT bone scan base evidence disease progression bone metastasis ( new lesion growth exist lesion ) , OR 3 . Evidence symptomatic progression ( increase pain area know lesion confirm image ) . 10 . All acute toxic effect prior treatment resolve NCICTCAE v4.0 Grade 2 less . 11 . Men childbearing potential must agree use adequate contraception begin sign ICF least 30 day last dose study drug . The definition adequate contraception base judgment principal investigator designate associate . 12 . Acceptable hematology serum biochemistry screen value : White Blood Cell Count ( WBC ) ≥ 3,000/mm3 Absolute Neutrophil Count ( ANC ) ≥ 1,500/mm3 Platelet ( PLT ) count ≥ 100,000/mm3 Hemoglobin ( HGB ) ≥ 9.0 g/dl Total bilirubin level ≤ 1.5 x institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN Creatinine ≤ 1.5 x ULN Albumin &gt; 2.5 g/dL 13 . Willing able comply protocol , include followup visit examination 1 . Treatment cytotoxic chemotherapy within previous 4 week , failure recover AEs grade 2 less due cytotoxic chemotherapy administer 4 week previous ( however , ongoing neuropathy permit ) 2 . Receiving concurrent systemic therapy radionuclides ( e.g. , strontium89 , samarium153 , rhenium186 , rhenium188 ) treatment bony metastasis . Prior therapy radium223 permit . 3 . Other malignancy treat within last 3 year ( except non melanoma skin cancer lowgrade superficial bladder cancer ) 4 . Visceral ( i.e . liver , lung , etc ) metastasis ( pulmonary nodule ≤1cm permit ) assess chest , abdominal pelvic compute tomography ( CT ) ( image modality ) 5 . Presence active untreated CNS parenchymal epidural spinal metastasis 6 . Lymphadenopathy exceed 3 cm shortaxis diameter 7 . Imminent spinal cord compression base clinical finding and/or magnetic resonance imaging ( MRI ) . Treatment complete spinal cord compression . 8 . Any serious illness medical condition , limited : Any infection ≥ National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) version 4.0 Grade 2 Cardiac failure New York Heart Association ( NYHA ) III IV Crohn 's disease ulcerative colitis Bone marrow dysplasia Fecal incontinence 9 . Inability comply protocol and/or willing available followup assessment . 10 . Any condition , investigator 's opinion , make subject unsuitable trial participation . 11 . Concurrent cytotoxic chemotherapy anticancer therapy abiraterone , prednisone glucocorticoid , enzalutamide , androgen deprivation therapy , bisphosphonates , denosumab . 12 . Concurrent use another investigational drug device therapy ( i.e. , outside study treatment ) , within 2 week treatment initiation . 13 . Major surgery within 30 day prior start study drug .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>